Statins in solid organ transplantation: Is there an immunosuppressive effect?

American Journal of Transplantation

Volumn 4, Issue 7, 2004, Pages 1013-1018

  Kobashigawa, Jon A ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

Hyperlipidemia; Immunomosuppressive effects; Statins; Transplantation

Indexed keywords

A 228839; ANTILIPEMIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUINDOSTATIN; GAMMA INTERFERON; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUKOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINIC ACID; PRAVASTATIN; PREDNISOLONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SIMVASTATIN; STATINE;

ALLOGRAFT; ATHEROSCLEROSIS; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; EVIDENCE BASED MEDICINE; HEART TRANSPLANTATION; HISTOCOMPATIBILITY; HUMAN; HYPERLIPIDEMIA; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOCYTE FUNCTION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY; SIDE EFFECT; SURGICAL PATIENT; TREATMENT OUTCOME; VASCULAR DISEASE;

ARTERIOSCLEROSIS; CHOLESTEROL; CLINICAL TRIALS; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; KIDNEY TRANSPLANTATION; LIPID METABOLISM; MAJOR HISTOCOMPATIBILITY COMPLEX; ORGAN TRANSPLANTATION; TRANSPLANTATION CONDITIONING;

EID: 3042741083     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00475.x     Document Type: Short Survey

References (33)

1. Johnson MR. Transplant coronary disease: Non-immunologic risk factors. J Heart Lung Transplant 1992; 11: S124-S132.
2. Shephard J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
4. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.
5. Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-844.
6. Kobashigawa JA, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-627.
7. Cutts JL, Scallen TJ, Watson J, Bankhurst AD. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol 1989; 139: 550-557.
8. Wenke K, Meiser B, Thiery J et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997; 96: 1398-1402.
9. Weis M, Pehlivanli S, Meiser BM, von Scheidt W. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation. J Am Coll Cardiol 2001; 38: 814-818.
10. Ballantyne CM, Short BC, Bourge RC et al. Lipid treatment and survival after heart transplantation [abstract]. J Am Coll Cardiol 1998; 31 (Suppl. 1): 157.
11. Mehra MR, Uber PA, Vivekananthan K et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 2002; 40: 1609-1614.
12. Katznelson S, Wilkinson AH, Kobashigawa JA et al. The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation 1996; 61: 1469-1474.
13. Kasiske BL, Heim-Duthoy KL, Singer GG, Watschinger B, Germain MJ, Bastani B. The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation 2001; 72: 223-227.
14. Holdaas H, Jardine AG, Wheeler DC et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int 2001; 60: 1990-1997.
15. Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024-2031.
16. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation (Review). Transplantation 1997; 63: 331-338.
17. Bruschke AV, Kramer JR Jr, Bal ET, Haque IU, Detrano RC, Goormastic M. The dynamics of progression of coronary atherosclerosis studied in 168 medically treated patients who underwent coronary arteriography three times. Am Heart J 1989; 117: 296-305.
18. Yokoya K, Takatsu H, Suzuki T et al. Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis: a study based on four serial coronary arteriograms per year. Circulation 1999; 100: 903-909.
19. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996; 94: 2013-2020.
20. Libby P. Inflammation in atherosclerosis (Review). Nature 2002; 420 (6917): 868-874.
21. Yamani MH, Masri S, Ratliff NB et al. The role of vitronectin receptor and tissue factor in the pathogenesis of transplant coronary vasculopathy. J Heart Lung Transplant 2001; 20: 185.
22. Pattison JM, Nelson PJ, Huie P, Sibley RK, Krensky AM. RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J Heart Lung Transplant 1996; 15: 1194-1199.
23. Yun JJ, Fischbein MP, Laks H et al. Rantes production during development of cardiac allograft vasculopathy. Transplantation 2001; 71: 1649-1656.
24. Palinski W, Tsimikas S. Immunomodulatory effects of statins: mechanisms and potential impact on arteriosclerosis. J Am Soc Nephrol 2002; 13: 1673-1681.
25. Akhlaghi F, Ashley J, Keogh A, Brown K. Cyclosporine plasm unbound fraction in heart and lung transplantation recipients. Ther Drug Monit 1999; 21: 8-16.
26. Regazzi MB, Iacona I, Campana C, Gavazzi A, Vigano M, Perani G. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporine A. Transplant Proc 1994; 26: 2644-2645.
27. McPherson R, Tsoukas C, Baines MG et al. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol 1993; 13: 439-444.
28. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-1402.
29. Weitz-Schmidt G, Welzenbach K, Brinkmann V et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687-692.
30. Liu L, Moesner P, Kovach NL et al. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). J Biol Chem 1999; 274: 33334-33340.
31. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 1998; 83: 683-690.
32. Wei X, Si MS, Imagawa DK, Ping J, Tromberg BJ, Cahalan MD. Perillyl alcohol inhibits TCR-mediated calcium signaling, alters cell shape and motility, and induces apoptosis in T lymphocytes. Cell Immunol 2000; 20: 6-13.
33. Si MS, Ji P, Tromberg BJ et al. Farnesyltransferase inhibition: a novel method of immunomodulation. Int Immunopharmacol 2003; 3: 475-483.